Certain Common Stock of Krystal Biotech, Inc. are subject to a Lock-Up Agreement Ending on 17-JAN-2019.
January 17, 2019
Share
Certain Common Stock of Krystal Biotech, Inc. are subject to a Lock-Up Agreement Ending on 17-JAN-2019. These Common Stock will be under lockup for 91 days starting from 18-OCT-2018 to 17-JAN-2019.
Details:
The directors and executive officers have agreed that they will not offer for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any shares of common stock or any securities convertible into, or exercisable or exchangeable for, shares of common stock, for a period of 90 days from the date of final prospectus without the prior written consent of Cowen and Company, LLC and William Blair & Company, LLC.
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patientâs skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
KRYSTAL BIOTECH, INC. 
